[HTML][HTML] Annexin A1–containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair

G Leoni, PA Neumann, N Kamaly… - The Journal of …, 2015 - Am Soc Clin Investig
G Leoni, PA Neumann, N Kamaly, M Quiros, H Nishio, HR Jones, R Sumagin, RS Hilgarth…
The Journal of clinical investigation, 2015Am Soc Clin Investig
Epithelial restitution is an essential process that is required to repair barrier function at
mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in
inflammation and further damage; therefore, a better understanding of the epithelial
restitution process has potential for improving the development of therapeutics. In this work,
we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of
extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1 …
Epithelial restitution is an essential process that is required to repair barrier function at mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in inflammation and further damage; therefore, a better understanding of the epithelial restitution process has potential for improving the development of therapeutics. In this work, we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1-containing EVs activate wound repair circuits. Compared with healthy controls, patients with active inflammatory bowel disease had elevated levels of secreted ANXA1-containing EVs in sera, indicating that ANXA1-containing EVs are systemically distributed in response to the inflammatory process and could potentially serve as a biomarker of intestinal mucosal inflammation. Local intestinal delivery of an exogenous ANXA1 mimetic peptide (Ac2-26) encapsulated within targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated healing of murine colonic wounds after biopsy-induced injury. Moreover, one-time systemic administration of Ac2-26 Col IV NPs accelerated recovery following experimentally induced colitis. Together, our results suggest that local delivery of proresolving peptides encapsulated within nanoparticles may represent a potential therapeutic strategy for clinical situations characterized by chronic mucosal injury, such as is seen in patients with IBD.
The Journal of Clinical Investigation